Tel Aviv, Israel – September 18, 2026 -- Lutris Pharma will present updated phase 2 clinical data for its topical B-Raf inhibitor LUT014 at the 35th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, running September 30 through October 3.

Cambridge – September 18, 2026 -- Nona Biosciences has developed HCAbLM, the first language model trained specifically on fully human heavy-chain-only antibodies (HCAbs), built from a dataset of 31.8 million HCAb sequences drawn from 73 independently immunized transgenic mice. The findings were detailed in a study titled "A foundation model learns the sequence and functional grammar of fully human heavy-chain-only antibodies," published on bioRxiv.

Valby, Denmark – – September 18, 2026 -- H. Lundbeck A/S has secured marketing authorization from Japan's Ministry of Health, Labour and Welfare for eptinezumab, branded Vyepti, as a preventive treatment for migraine attacks in adults, opening the company's first independent product launch in the country.

Washington, D.C. – – September 18, 2026 -- Advocates for limb-girdle muscular dystrophy (LGMD) held more than 60 meetings with congressional offices this week, representing patients from over 20 states, as part of The Speak Foundation's LGMD Day on the Hill.

Pittsburgh – September 18, 2026 -- PhaseWell Research has acquired Community Clinical Research (CCR), an Austin, Texas-based inpatient-capable CNS clinical trial site, in a deal advised exclusively by The Braff Group. The transaction gives PhaseWell, a Shore Capital Partners portfolio company headquartered in Nashville, its first inpatient neuropsychiatric research capability.

Edina, Minn. – September 18, 2026 -- ReEmerge, Inc. has closed an oversubscribed $37 million Series A financing and exited stealth mode to advance a novel therapy targeting chronic cognitive impairment caused by traumatic brain injury (TBI).

Dallas – September 18, 2026 -- Nanoscope Therapeutics will unveil four-year follow-up data showing sustained visual acuity gains from its gene therapy MOGENRY® in retinitis pigmentosa patients, with the FDA already having accepted and filed the company's Biologics License Application.

Boston – September 17, 2026 -- Xylo Bio has dosed the first participants in a Phase 1 clinical trial of XYL-1001, a selective 5-HT2A receptor agonist targeting major depressive disorder (MDD), marking the company's transition to a clinical-stage biotechnology organization.

Stockholm – September 17, 2026 -- SciBase Holding AB has pushed back the first day of trading in subscription rights and paid subscribed shares (BTA) tied to its ongoing rights issue by one day, moving the start date from September 15, 2026 to September 16, 2026 on Nasdaq First North Growth Market.

The subscription period itself remains unchanged, running from September 15 through September 29, 2026.

Evanston, Illinois – September 17, 2026 -- ZS has been named a Leader in the IDC MarketScape: Worldwide Life Science R&D RWD/Real-World Evidence for Data Platforms, Technology Solutions, and Consulting Services 2026 Vendor Assessment (IDC #US54122226, August 2026).

The recognition marks ZS's second IDC MarketScape Leader designation in 2026, following its May 2026 placement as a Leader in the Worldwide Life Sciences R&D Strategic Consulting Services assessment (IDC #US53009826).